BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33921192)

  • 21. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
    Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
    Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimaphilin inhibits human osteosarcoma cell invasion and metastasis through suppressing the TGF-β1-induced epithelial-to-mesenchymal transition markers via PI-3K/Akt, ERK1/2, and Smad signaling pathways.
    Dong F; Liu T; Jin H; Wang W
    Can J Physiol Pharmacol; 2018 Jan; 96(1):1-7. PubMed ID: 28177668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
    Song X; Zhou X; Qin Y; Yang J; Wang Y; Sun Z; Yu K; Zhang S; Liu S
    Int J Mol Med; 2018 Jul; 42(1):579-588. PubMed ID: 29693154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IM-412 inhibits the invasion of human breast carcinoma cells by blocking FGFR-mediated signaling.
    Jung SY; Yi JY; Kim MH; Song KH; Kang SM; Ahn J; Hwang SG; Nam KY; Song JY
    Oncol Rep; 2015 Nov; 34(5):2731-7. PubMed ID: 26351897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
    Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
    Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sildenafil Inhibits the Growth and Epithelial-to-mesenchymal Transition of Cervical Cancer via the TGF-β1/Smad2/3 Pathway.
    Liu P; Pei JJ; Li L; Li JW; Ke XP
    Curr Cancer Drug Targets; 2023; 23(2):145-158. PubMed ID: 35975844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Astragaloside IV inhibits TGF-β1-induced epithelial-mesenchymal transition through inhibition of the PI3K/Akt/NF-κB pathway in gastric cancer cells.
    Zhu J; Wen K
    Phytother Res; 2018 Jul; 32(7):1289-1296. PubMed ID: 29480652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Taxifolin inhibits breast cancer cells proliferation, migration and invasion by promoting mesenchymal to epithelial transition via β-catenin signaling.
    Li J; Hu L; Zhou T; Gong X; Jiang R; Li H; Kuang G; Wan J; Li H
    Life Sci; 2019 Sep; 232():116617. PubMed ID: 31260685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Babao Dan inhibits the migration and invasion of gastric cancer cells by suppressing epithelial-mesenchymal transition through the TGF-β/Smad pathway.
    Liu J; Chen Y; Cao Z; Guan B; Peng J; Chen Y; Zhan Z; Sferra TJ; Sankararaman S; Lin J
    J Int Med Res; 2020 Jun; 48(6):300060520925598. PubMed ID: 32529872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
    Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
    Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
    Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
    Pattarawat P; Hunt JT; Poloway J; Archibald CJ; Wang HR
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):415-425. PubMed ID: 34043046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
    Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway.
    Li W; Ma J; Ma Q; Li B; Han L; Liu J; Xu Q; Duan W; Yu S; Wang F; Wu E
    Curr Med Chem; 2013; 20(33):4185-4194. PubMed ID: 23992306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemifloxacin inhibits migration and invasion and induces mesenchymal-epithelial transition in human breast adenocarcinoma cells.
    Chen TC; Hsu YL; Tsai YC; Chang YW; Kuo PL; Chen YH
    J Mol Med (Berl); 2014 Jan; 92(1):53-64. PubMed ID: 24005829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Embryonic stem cell secreted factors decrease invasiveness of triple-negative breast cancer cells through regulome modulation.
    Tarasewicz E; Oakes RS; Aviles MO; Straehla J; Chilton KM; Decker JT; Wu J; Shea LD; Jeruss JS
    Cancer Biol Ther; 2018 Apr; 19(4):271-281. PubMed ID: 29053396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dihydroartemisinin inhibits the tumorigenesis and metastasis of breast cancer via downregulating CIZ1 expression associated with TGF-β1 signaling.
    Li Y; Zhou X; Liu J; Gao N; Yang R; Wang Q; Ji J; Ma L; He Q
    Life Sci; 2020 May; 248():117454. PubMed ID: 32088211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.